US
Therapeutic Areas
CoA Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BBP-671 | Pantothenate Kinase-Associated Neurodegeneration (PKAN) | Phase 1 |
Leadership Team at CoA Therapeutics
CS
Christine Siu
Chief Executive Officer, in Residence
AW
Anna Wade, Ph.D.
Chief Operating Officer
A'
Agnieszka 'AJ' Jurecka, M.D., Ph.D.
Vice President, Clinical Development
JP
Jennifer Pavillard
Vice President, Regulatory Affairs
NK
Neil Kumar, Ph.D.
Board of Directors